Case Studies

Challenge: A pharma company developing a first-in-class therapeutic to treat rare paediatric neurodegenerative disorders was nearing NDA approval in multiple indications and was ready to initiate...

Challenge: A midsize speciality pharmaceuticals company has retained Alacrita to conduct a series of due diligence assessments to support its business development function. The client focuses on a...

Challenge: Our client was a publicly-traded clinical-stage biopharmaceutical company using an epigenetic approach modulate gene expression in tumor and immune cells to treat cancer. Their lead...

Challenge: Our client, a global pharmaceutical company, was facing a short deadline to making an offer for a late stage gene therapy asset and was under considerable competitive deal pressure. This...

Over the past decade, our life science consulting team has provided expert guidance and hands-on support to companies, investors and academic research centers. What makes us unique is the first-hand...

Challenge: A VC investor considering funding a radiopharmaceutical company requested an analysis of the therapeutic radiopharmaceutical landscape, to help them evaluate the investment. The purpose of...

Challenge: A private equity client assessing a major investment asked Alacrita to research and assess the business development landscape for potential in-licensing or acquisition deals that could be...

Challenge: A European investor asked Alacrita to conduct a due diligence exercise on a company that had developed a novel single chain antibody platform with its lead product in ADC format ahead of a...

Challenge: A biotech client had developed a generic version of a major anti-diabetic peptide drug, and wanted a clearer understanding of the product's registrability, as well as support with defining...

Challenge: A European publicly-listed biotech was facing a Phase III milestone for its lead immunomodulator and had a next generation technology in IND-enabling studies. The company was operating in...

Project Challenge: An early stage investor was in the midst of setting up a NewCo for the research and development of novel treatments using a fairly under-researched area of cell biology. However, a...

Due Diligence Challenge: An investor was considering re-investing into a development-stage microbiome company that had experienced certain issues that delayed timelines and changed the risk profile....